Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarks on its Most Ambitious Hypertension Clinical Study Yet: HYPER-H21-4
Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and it's most ambitious yetThis study builds on the HYPER-H21-1 and HYPER-H21-2 findings, as well as the HYPER-H21-3 study that is set to begin dosing in mid-November 2021Lexaria’s goal is to pursue regulatory approval for its proprietary DehydraTECH-CBD for potential use as a treatment for high blood pressureStudy protocols are being readied for…